文献速递妇科肿瘤支持与姑息治疗

降低风险输卵管卵巢切除术后激素替代治疗可减轻内分泌与性问题:一项前瞻性研究

Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
PubMed 文献 · Eur J Cancer · 2017-09-04

这项前瞻性观察研究纳入178例卵巢癌高风险绝经前女性,57例选择降低风险输卵管卵巢切除术(RRSO),121例选择妇科筛查(GS)。RRSO后27例使用激素替代治疗(HRT)、30例未使用;未使用HRT者总体内分泌症状与性不适较使用者显著增加,HRT使用者与GS组各结局随时间无显著差异。

要点

  • RRSO后未用HRT者内分泌症状较使用者显著增加(p=0.001,ES=-0.40;p<0.001,ES=-0.59)。
  • RRSO后未用HRT者性不适较使用者显著增加(p<0.001,ES=0.74;p<0.001,ES=1.17)。
  • HRT使用者与GS组各结局随时间无显著差异。

核心结论

  • 作者认为,RRSO后第一年使用HRT对绝经前女性的内分泌症状和性症状有减轻作用。

研究设计与样本

  • 前瞻性观察研究,纳入178例卵巢癌高风险绝经前女性,57例选择RRSO,121例选择妇科筛查(GS)。
  • RRSO组中27例术后使用HRT(HRT使用者),30例未使用(HRT未使用者)。
  • 术前(T1)及术后3个月(T2)、9个月(T3)或GS组对应时间点填写问卷,内分泌症状用FACT-ES评估,性功能用SAQ评估。

主要发现

  • 基线时各组结局变量无显著差异。
  • 与HRT使用者相比,HRT未使用者总体内分泌症状显著增加(T1:p=0.001,ES=-0.40;T2:p<0.001,ES=-0.59)。
  • 与HRT使用者相比,HRT未使用者性不适显著增加(p<0.001,ES=0.74;p<0.001,ES=1.17)。
  • 效应量≥0.50通常被认为具有临床相关性。
  • HRT使用者与GS组在任何结局上随时间均无显著差异。

关键数值与推荐

  • FACT-ES用于评估绝经症状,SAQ用于评估性功能。
  • 效应量0.50或以上通常被认为具有临床相关性。
  • 连续变量采用重复测量混合效应模型比较,纵向有序分类数据采用广义估计方程。

临床怎么用

  • 作者认为RRSO后第一年使用HRT可减轻绝经前女性的内分泌症状和性症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been some doubts raised in earlier studies about the efficacy of hormone replacement therapy (HRT) in reducing endocrine and sexual problems in women who have undergone a risk-reducing salpingo-oophorectomy (RRSO). METHODS: In this prospective, observational study, we recruited 178 premenopausal women with a high risk for ovarian cancer. Fifty-seven women opted for RRSO and 121 for gynaecological screening (GS). Women completed questionnaires before surgery (T1) and 3 (T2) and 9 (T3) months post surgery, or at equivalent time points for the GS-group. Menopausal symptoms were assessed with the Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) and sexual functioning with the Sexual Activity Questionnaire (SAQ). Groups were compared using repeated measures mixed effect models for continuous variables, and generalised estimating equations for longitudinal ordered categorical data. RESULTS: Twenty-seven women who underwent RRSO used HRT after surgery (HRT-users) and 30 did not (HRT-non-users). There were no significant group differences at baseline on the outcome variables. Compared to the HRT-users, the HRT-non-users exhibited a significant increase in overall endocrine symptoms (p = 0.001, effect size (ES) = -0.40 and p < 0.001, ES = -0.59 at T1 and T2, respectively), and in sexual discomfort (p < 0.001, ES = 0.74 and p < 0.001, ES = 1.17). The effect size provides an indication of the magnitude of the observed group differences. An effect size of 0.50 or greater is generally considered to be clinically relevant. No significant differences over time were observed between the HRT-users and the GS-group on any of the outcomes. CONCLUSION: Our results suggest that HRT use in the first year after RRSO has beneficial effects in terms of minimising endocrine symptoms and sexual symptoms in premenopausal women who have undergone RRSO.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vermeulen RFM, Beurden MV, Kieffer JM, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. Eur J Cancer. 2017. PMID: 28818705. doi:10.1016/j.ejca.2017.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。